Interview with Josh Hardman of Psychedelic Alpha on building psychedelic investment research and evaluating early-stage opportunities

Psychedelic Alpha and Josh Hardman focus on how psychedelic industry research and investing can be approached with discipline, including evaluating early-stage projects. The interview centers on what information matters when assessing psychedelic opportunities, such as track record, scientific or clinical credibility, regulatory pathway readiness, and practical execution. The discussion frames psychedelics as an emerging sector where data-driven analysis, risk management, and clear decision criteria are important for separating hype from investable progress.